https://www.selleckchem.com/pr....oducts/tinengotinib.
0001, and delayed phase (DP), p 0.0001. Image noise was significantly lower in IMR-LDCT compared to iDose -SDCT in AP, portal venous phase, and DP with p 0.0001. IMR-LDCT showed significantly higher SNR (p 0.0001) and SNR (p 0.0001) compared to iDose -SDCT. On subjective analysis, IMR-LDCT images showed better image quality in AP, portal venous phase, and DP and better tumor conspicuity in AP and DP. IMR-LDCT (21.4 ± 4.6 mSv) achieved 36.9% reduction in the effective dose compared to iDose -SDCT (33.9 ± 6.2 mSv)
Like
Comment
Share
